摘要
慢性淋巴细胞白血病（CLL）是白血病的一种亚型,以不成熟的淋巴细胞扩散到血液、骨髓和淋巴组织中为特点。CLL是一种极为异质性的疾病,可以表现为无症状生存几十年,也可表现为快速进展。因此,对于CLL需要进行个体化治疗。传统治疗药物包括苯丁酸氮芥、氟达拉滨、环磷酰胺及利妥昔单抗等的单药或联合应用。
Chronic lymphocytic leukemia（CLL）is a subtype of leukemia arising from immunologically less mature lymphocytes that spread to the blood,bone marrow,and lymphatic tissues.CLL is an extremely heterogenous disease that can range from asymptomatic for decades to rapidly progressive disease.Therefore,CLL patients should receive individualized treatment.The traditional drugs include chlorambucil,fludarabine,cyclophosphamide and rituximab.Subsequently,an enhanced understanding of the mechanisms involved in CLL led to new,more targeted treatments.In this review article,we discuss in detail several novel agents that are being studied or approved for the treatment of CLL,including new anti-CD20 monoclonal antibodies（ofatumumab and obinutuzumab）,phosphatidylinositol 3-kinase inhibitors（idelalisib and IPI-145）,Bruton tyrosine kinase inhibitors（ibrutinib）,B cell lymphoma 2inhibitors（ABT-263 and ABT-199）,cyclin-dependent kinase inhibitors（flavopiridol and dinaciclib）,immunomodulators（lenalidomide）and chimeric antigen receptor T-cell therapy.
出处
《临床血液学杂志》
CAS
2016年第4期604-608,共5页
Journal of Clinical Hematology
